Musaddiq J Awan1, Pierre Lavertu2, Chad Zender2, Rod Rezaee2, Nicole Fowler2, Lilit Karapetyan3, Michael Gibson3, Jay Wasman4, Peter Faulhaber5, Mitchell Machtay6, Min Yao6. 1. Department of Radiation Oncology, Case Western Reserve University and University Hospitals, 11100 Euclid Avenue, Cleveland, OH, 44114, USA. Musaddiq.Awan@UHHospitals.org. 2. Department of Otolaryngology and Head and Neck Surgery, University Hospitals, Cleveland, OH, USA. 3. Department of Medical Oncology, University Hospitals, Cleveland, OH, USA. 4. Department of Pathology, University Hospitals, Cleveland, OH, USA. 5. Department of Nuclear Medicine and Radiology, University Hospitals, Cleveland, OH, USA. 6. Department of Radiation Oncology, Case Western Reserve University and University Hospitals, 11100 Euclid Avenue, Cleveland, OH, 44114, USA.
Abstract
PURPOSE: To retrospectively review post-treatment (post-tx) FDG-PET/CT scans in patients with advanced head and neck squamous cell carcinoma (HNSCC) and known p16 status, treated with definitive (chemo)radiation (RT). METHODS: A total of 108 eligible patients had N2A or greater HNSCC treated with chemoRT from August 1, 2008, to February 28, 2015, with post-tx PET/CT within 6 months after RT. Kaplan-Meier curves, log-rank statistics, and Cox proportional hazards regression were used for statistical analysis. RESULTS: Median follow-up was 2.38 years. Sixty-eight (63.0%) patients had p16+ and 40 (37.0%) had p16- status. Two-year overall survival and recurrence-free survival were 93.4% and 77.8%, respectively. The negative predictive value (NPV) of PET/CT for local recurrence (LR) was 100%. The NPV for regional recurrence (RR) was 96.5% for all patients, 100% for p16+ patients, and 88.5% for p16- patients. The positive predictive value (PPV) of PET/CT for recurrence was 77.3% for all patients, 50.0% for p16+, and 78.6% for p16-. The PPV for LR was 72.7% for all patients, 50.0% for p16+ patients, and 72.7% for p16- patients. The PPV for RR was 50.0% for all patients, 33% for p16+, and 66.6% for p16-. Post-tx PET/CT and p16 status were independent predictors of recurrence-free survival (p < 0.01). CONCLUSIONS: Post-tx PET/CT predicts treatment outcomes in both p16 + and p16- patients, and does so independently of p16 status. P16- patients with negative PET have a 10% risk of nodal recurrence, and closer follow-up in these patients is warranted.
PURPOSE: To retrospectively review post-treatment (post-tx) FDG-PET/CT scans in patients with advanced head and neck squamous cell carcinoma (HNSCC) and known p16 status, treated with definitive (chemo)radiation (RT). METHODS: A total of 108 eligible patients had N2A or greater HNSCC treated with chemoRT from August 1, 2008, to February 28, 2015, with post-tx PET/CT within 6 months after RT. Kaplan-Meier curves, log-rank statistics, and Cox proportional hazards regression were used for statistical analysis. RESULTS: Median follow-up was 2.38 years. Sixty-eight (63.0%) patients had p16+ and 40 (37.0%) had p16- status. Two-year overall survival and recurrence-free survival were 93.4% and 77.8%, respectively. The negative predictive value (NPV) of PET/CT for local recurrence (LR) was 100%. The NPV for regional recurrence (RR) was 96.5% for all patients, 100% for p16+ patients, and 88.5% for p16- patients. The positive predictive value (PPV) of PET/CT for recurrence was 77.3% for all patients, 50.0% for p16+, and 78.6% for p16-. The PPV for LR was 72.7% for all patients, 50.0% for p16+ patients, and 72.7% for p16- patients. The PPV for RR was 50.0% for all patients, 33% for p16+, and 66.6% for p16-. Post-tx PET/CT and p16 status were independent predictors of recurrence-free survival (p < 0.01). CONCLUSIONS: Post-tx PET/CT predicts treatment outcomes in both p16 + and p16- patients, and does so independently of p16 status. P16- patients with negative PET have a 10% risk of nodal recurrence, and closer follow-up in these patients is warranted.
Entities:
Keywords:
Head and neck cancer; Human papillomavirus; Neck dissection; PET/CT; Prognostic factors
Authors: Sandro V Porceddu; David I Pryor; Elizabeth Burmeister; Bryan H Burmeister; Michael G Poulsen; Matthew C Foote; Benedict Panizza; Scott Coman; David McFarlane; William Coman Journal: Head Neck Date: 2011-01-14 Impact factor: 3.147
Authors: James D Murphy; Trang H La; Karen Chu; Andrew Quon; Nancy J Fischbein; Peter G Maxim; Edward E Graves; Billy W Loo; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2010-06-18 Impact factor: 7.038
Authors: Anuj Goenka; Luc G T Morris; Shyam S Rao; Suzanne L Wolden; Richard J Wong; Dennis H Kraus; Nisha Ohri; Jeremy Setton; Benjamin H Lok; Nadeem Riaz; Borys R Mychalczak; Heiko Schoder; Ian Ganly; Jatin P Shah; David G Pfister; Michael J Zelefsky; Nancy Y Lee Journal: Int J Cancer Date: 2013-03-29 Impact factor: 7.396
Authors: Min Yao; Michael M Graham; Russell B Smith; Kenneth J Dornfeld; Mark Skwarchuk; Henry T Hoffman; Gerry F Funk; Scott M Graham; Yusuf Menda; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2004-12-01 Impact factor: 7.038
Authors: Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Jason Y K Chan; Giuseppe Sanguineti; Jeremy D Richmon; Shanthi Marur; Christine G Gourin; Wayne Koch; Christine H Chung; Harry Quon; Justin A Bishop; Nafi Aygun; Nishant Agrawal Journal: Arch Otolaryngol Head Neck Surg Date: 2012-11
Authors: M R Posner; J H Lorch; O Goloubeva; M Tan; L M Schumaker; N J Sarlis; R I Haddad; K J Cullen Journal: Ann Oncol Date: 2011-02-11 Impact factor: 32.976
Authors: Hisham Mehanna; Wai-Lup Wong; Christopher C McConkey; Joy K Rahman; Max Robinson; Andrew G J Hartley; Christopher Nutting; Ned Powell; Hoda Al-Booz; Martin Robinson; Elizabeth Junor; Mohammed Rizwanullah; Sandra V von Zeidler; Hulya Wieshmann; Claire Hulme; Alison F Smith; Peter Hall; Janet Dunn Journal: N Engl J Med Date: 2016-03-23 Impact factor: 91.245
Authors: Louise Madeleine Risør; Annika Loft; Anne Kiil Berthelsen; Frederik Cornelius Loft; Andreas Ruhvald Madsen; Ivan Richter Vogelius; Andreas Kjær; Jeppe Friborg Journal: Eur Arch Otorhinolaryngol Date: 2019-10-23 Impact factor: 2.503
Authors: Yan Li; Musaddiq J Awan; Tangel Chang; Pierre Lavertu; Chad Zender; Rod Rezaee; Nicole Fowler; Jay Wasman; Norbert E Avril; Nianyong Chen; Mitchell Machtay; Min Yao Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-24 Impact factor: 9.236
Authors: Zsuzsanna Iyizoba-Ebozue; Sarah Billingsley; Russell Frood; Sriram Vaidyanathan; Andrew Scarsbrook; Robin J D Prestwich Journal: Cancers (Basel) Date: 2022-09-26 Impact factor: 6.575